Tyler Jacks
Direttore/Membro del Consiglio presso THERMO FISHER SCIENTIFIC
Patrimonio netto: 9 M $ in data 30/04/2024
Profilo
Tyler E.
Jacks is the founder of T2 Biosystems, Inc. (founded in 2006) and Dragonfly Therapeutics, Inc. (founded in 2016).
He currently holds positions as an Independent Director at Amgen, Inc. (since 2012), Director at Thermo Fisher Scientific, Inc. (since 2009), President & Director at Commonwealth Cancer Consortium, Inc. (since 2021), and Professor at Massachusetts Institute of Technology (since 2007).
Dr. Jacks previously served as Chairman at the National Cancer Institute and as Director at the David H.
Koch Institute for Integrative Cancer Research (from 2007 to 2021).
He received his undergraduate degree from Harvard University in 1983 and his doctorate degree from The University of California, San Francisco in 1988.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 22/05/2024 | 8 398 ( 0.00% ) | 5 M $ | 30/04/2024 | |
AMGEN INC.
0.00% | 01/04/2024 | 15 286 ( 0.00% ) | 4 M $ | 30/04/2024 |
Posizioni attive di Tyler Jacks
| Società | Posizione | Inizio |
|---|---|---|
| THERMO FISHER SCIENTIFIC | Direttore/Membro del Consiglio | 26/05/2009 |
| AMGEN INC. | Direttore/Membro del Consiglio | 01/01/2012 |
| Massachusetts Institute of Technology | Corporate Officer/Principal | 01/01/2007 |
| Commonwealth Cancer Consortium, Inc. | Presidente | 01/02/2021 |
Precedenti posizioni note di Tyler Jacks
| Società | Posizione | Fine |
|---|---|---|
David H. Koch Institute for Integrative Cancer Research
 David H. Koch Institute for Integrative Cancer Research Miscellaneous Commercial ServicesCommercial Services David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA. | Direttore/Membro del Consiglio | 01/01/2021 |
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Presidente | 01/01/2016 |
| T2 BIOSYSTEMS, INC. | Fondatore | 01/01/2013 |
Dragonfly Therapeutics, Inc.
 Dragonfly Therapeutics, Inc. BiotechnologyHealth Technology Dragonfly Therapeutics, Inc. develops therapy to stimulate immune responses against cancer. The company was founded by Tyler Jacks, Bill Haney and David Raulet in 2015 and is headquartered in Waltham, MA. | Fondatore | - |
Formazione di Tyler Jacks
| Harvard University | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| THERMO FISHER SCIENTIFIC | Health Technology |
| T2 BIOSYSTEMS, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Miscellaneous |
David H. Koch Institute for Integrative Cancer Research
David H. Koch Institute for Integrative Cancer Research Miscellaneous Commercial ServicesCommercial Services David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA. | Commercial Services |
Dragonfly Therapeutics, Inc.
Dragonfly Therapeutics, Inc. BiotechnologyHealth Technology Dragonfly Therapeutics, Inc. develops therapy to stimulate immune responses against cancer. The company was founded by Tyler Jacks, Bill Haney and David Raulet in 2015 and is headquartered in Waltham, MA. | Health Technology |
| Commonwealth Cancer Consortium, Inc. |
- Borsa valori
- Insiders
- Tyler Jacks
